HIVE vs CIFR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

HIVE

57.7
AI Score
VS
HIVE Wins

CIFR

57.3
AI Score

Investment Advisor Scores

HIVE

58score
Recommendation
HOLD

CIFR

57score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE CIFR Winner
Forward P/E 62.8931 85.4701 HIVE
PEG Ratio 0 0 Tie
Revenue Growth 73.5% -43.0% HIVE
Earnings Growth -99.9% 19.5% CIFR
Tradestie Score 57.7/100 57.3/100 HIVE
Profit Margin -98.5% 0.0% CIFR
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

HIVE 1M: -42.1% · 3M: -34.1% CIFR 1M: -54.7% · 3M: -64.1%

Current Technical Phase

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.7%), weak momentum, RSI 24

RSI (14): 23.9 · Price: $1.95

CIFR

Markdown
Sell / avoid

Price below a falling SMA50 (slope -16.2%), weak momentum, RSI 22

RSI (14): 22.0 · Price: $8.32

Fundamentals Snapshot

Metric HIVE CIFR
Market Cap — —
Forward P/E -3.8 37.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.7% -0.4%
Gross Margin 0.4% -0.1%
Operating Margin -0.6% -3.0%
EPS -1.32 -2.87
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.